US Pharma MarketingThe post En Carta secures $6.18m to expand molecular testing solutions appeared first on Medical Device Network.
En Carta secures $6.18m to expand molecular testing solutions
En Carta Diagnostics has announced the first closing of €5m ($6.18m) in financing to scale its at-home molecular diagnostic solutions. The funding comprises €3m in equity led by Blue Forest Ventures, and €2m in non-dilutive funding. En Carta Diagnostics is conducting two clinical trials of its Lyme detection product in Boston, US, and Bialystok, Poland. Credit: CrizzyStudio / Shutterstock.com. French deep-tech company En Carta Diagnostics has announced the first closing of €5m ($6.18m) in financing to scale its at-home molecular diagnostic solutions. The funding comprises €3m in equity investment led by Blue Forest Ventures, with participation from Ring Capital, existing…
En Carta Diagnostics has announced the first closing of €5m ($6.18m) in financing to scale its at-home molecular diagnostic solutions.
Source: Medical Device Network